Lipigon Pharmaceuticals AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was SEK 0.093 million compared to SEK 0.768 million a year ago. Net loss was SEK 12.65 million compared to SEK 10.38 million a year ago. Basic loss per share from continuing operations was SEK 1.3 compared to SEK 1.07 a year ago. Diluted loss per share from continuing operations was SEK 1.3 compared to SEK 1.07 a year ago.
For the six months, revenue was SEK 0.275 million compared to SEK 1.97 million a year ago. Net loss was SEK 21.67 million compared to SEK 15.26 million a year ago. Basic loss per share from continuing operations was SEK 2.23 compared to SEK 1.84 a year ago. Diluted loss per share from continuing operations was SEK 2.23 compared to SEK 1.84 a year ago.